By Karen Ivester, inSeption Group
In a macroeconomic downturn, the cost of staffing a clinical trial, procuring reagents, and stocking single-use supplies — among numerous other expenses — can range from inconvenient to disastrous. Trials examining CAR-T cell therapies, which require specialized expertise and materials, are among the hardest-hit.
However, economic downturns, while threatening and unwelcome, offer opportunities to improve operations through technology, training, and hiring. In some situations, organizations can benefit by claiming a manufacturing slot a failing project has vacated, advancing its own timeline.
It can be easy to instead react defensively. Life science company management can get caught up looking at the problems and challenges of tomorrow (e.g., an ongoing submission) without fully considering any given action’s effect on the organization’s entire portfolio of assets. Accordingly, five key strategies can help organizations planning or executing CAR-T cell therapy trials to not only endure macroeconomic hardship, but to emerge more efficient and well-prepared on the other side.